Forty percent of respondents had skipped a medical test or treatment to save on costs, and 32% had skipped filling a prescription (or took less medication than prescribed) because of costs.
NORC at the University of Chicago, together with the West Health Institute, released the results of a survey of American adults concerning their attitudes toward healthcare. They found that “healthcare costs have a significant and enduring impact on financial health.”
The survey was conducted among 1302 adults—providing a sample coverage of approximately 97% of US households—between February 15 and February 19 of this year using the AmeriSpeak Panel.
In the past year:
Other Americans reported going without care in order to save money, 40% of respondents had skipped a medical test or treatment to save on costs, and 32% had skipped filling a prescription (or took less medication than prescribed) because of costs.
Among those who had skipped a test or treatment, 60% said that they were afraid of the cost of a serious illness, while only 47% said that they were afraid of getting a serious illness itself. According to the report’s authors, these fears about the cost of treatment are often based on experience; more respondents who had negative financial impacts from previous healthcare costs (56%) feared paying for care than those who had not had previous experiences with financial hardship from healthcare costs (23%).
“It’s shocking and unacceptable that medical bills strike more fear in the hearts of Americans than serious illness,” said Shelley Lyford, president and CEO of West Health Institute, in a statement. “Americans are paying more for healthcare than they should and getting less than they deserve. Bold action is required to lower the sky-high cost of healthcare. The very health and wealth of our nation and its people are at stake.”
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.
Eye on Pharma: Keytruda Biosimilar Deal; German Court Bans Imraldi; New Biosimilars for Japan
July 31st 2025Alvotech and Dr. Reddy's partner to develop a Keytruda biosimilar, a German court bans Humira biosimilar over patent dispute, and Samsung Bioepis enters a strategic agreement with NIPRO Corporation in Japan.
Escaping the Void: All Things Biosimilars With Craig & G
July 31st 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."